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A B S T R A C T
Immune mediated inflammatory diseases (IMIDs) have similarities in pathophysiology and treatment. Not much
is known, however, about health-related quality of life (HR-QoL) in IMIDs. We assessed and compared HR-QoL,
using the validated EuroQoL 5-dimensions 5-levels questionnaire, in an observational cohort comprising 530
patients (67.5% female, mean age 49 years (95% CI 35.9–50.9), mean disease duration 31.0 months (95% CI
27.2–34.8)), with the following IMIDs: connective tissue diseases (32.6%), uveitis (20.8%), inflammatory ar-
thritis (17.7%), psoriasis (15.5%), vasculitis (6.2%), primary antiphospholipid syndrome (4.2%), and autoin-
flammatory diseases (2.8%). Patients used either no anti-inflammatory therapy (31.5%), monotherapy (28.7%),
or a combination of anti-inflammatory drugs (39.8%). The mean HR-QoL utility score was 0.75 (95% CI
0.72–0.78). Multinominal logistic regression analysis showed a statistically significant association between a
very low HR-QoL (utility score (< 0.70)) and female sex, rheumatological IMID or psoriasis, smoking or having
smoked in the past, and current biological disease modifying anti-rheumatic drugs use.
1. Introduction
Immune mediated inflammatory diseases (IMIDs) can induce organ
damage, physical disability, and impair work-related productivity
[1,2]. Importantly, IMIDs are not uncommon: the overall prevalence of
this group of diseases has been estimated to affect 5–7% of the popu-
lation in Europe and the United States [3]. Because IMIDs share
common immune pathogenic mechanisms, they are often treated with
the same medication.
In the last decades, treatment options for IMIDs have dramatically
improved [3,4]. Conventional disease modifying anti-rheumatic drugs
(cDMARDs), as mono- or combination therapy, became the cornerstone
of the treatment of many IMIDs. Additionally, initiation of treatment in
the early stage of the disease and tight control are now key elements in
the management of rheumatic conditions [5]. With the introduction of
biological DMARDs (bDMARDs), which target specific aspects of the
immune system, there is now a broad repertoire of anti-inflammatory
treatments available for patients with IMIDs.
Although modern treatment strategies led to improvement of out-
comes in IMIDs, such as the degree of inflammation and damage in
different organ systems, health-related quality of life (HR-QoL) is often
still compromised in patients with IMIDs. Multiple studies have eval-
uated the HR-QoL in individual IMIDs [6–8]. However, not much is
known about HR-QoL differences between different IMIDs that were
compared directly to one another in the same setting and using the
same methods. Yet, HR-QoL is important when understanding the im-
pact of disease on a patient's life and indirectly evaluating quality of
provided care.
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There are different ways to assess HR-QoL. The EuroQoL 5-dimen-
sions 5-levels (EQ-5D-5 L) is a generic questionnaire validated for the
assessment of HR-QoL and for economic analyses in the Netherlands
[9]. It covers five dimensions: mobility, self-care, usual activity, pain
and discomfort, and anxiety and depression. The Short Form-36 (SF-36)
is a 36-item patient-reported survey measuring health status in eight
domains (vitality, physical functioning, pain, physical, emotional and
social functioning and mental health) [10].
The main goal of this study was to assess and compare HR-QoL
scores with EQ-5D-5 L in patients with IMIDs across different depart-
ments in the University Medical Center Utrecht, Utrecht, The
Netherlands, and to identify determinants of reduced HR-QoL.
2. Methods
We conducted a cross-sectional analysis of baseline data from an
ongoing prospective cohort study (U-I&I) embedded in routine health
care to collect data on cardiovascular risk factors and quality of life of
patients with IMIDs.
2.1. Patients
All newly referred patients with existing or new-onset chronic IMIDs
visiting the outpatient clinics of the departments of Rheumatology and
Clinical immunology (henceforth referred to as Rheumatology),
Ophthalmology, and Dermatology at the University Medical Center
Utrecht were eligible for inclusion. The University Medical Center
Utrecht serves as a tertiary referral hospital for chronic IMIDs, and
patients were referred by either first-line care providers in the province
of Utrecht or by medical specialists in second-line regional hospitals
across the Netherlands. The most common reasons for referral included
requests for a second opinion related to diagnosis or treatment, a
medical indication for a complex therapeutic regimen, or the patient's
own preference. Most of the newly referred patients who already had a
diagnosis were previously diagnosed in a second-line regional hospital.
The Rheumatology department enrolled patients with any chronic
IMID as well as patients already enrolled in a linked cohort study on
systemic lupus erythematosus (SLE). The Ophthalmology department
enrolled patients diagnosed with uveitis and the Dermatology depart-
ment patients with psoriasis. Patients were enrolled by their own
physician, and all physicians working in the three participating de-
partments enrolled patients. All patients included in this analysis pro-
vided informed consent. The analyses presented in this paper used
linked anonymized routine health care data only.
2.2. Data collection
The data collection consisted of routine health care data extracted
from the hospital's electronic patient record system (Health care
Information Exchange, Chipsoft, Amsterdam, Netherlands) using en-
terprise data warehouse (Summa Data Solutions Raamsdonkveer, the
Netherlands) with SAS software (Version 9.4, Copyright © 2013 SAS
Institute Inc). In this paper, only data extracted from each patient's first
hospital visit was used, but in the ongoing cohort, data is extracted from
each patient record annually.
Some components of the routine data collection were standardized
whereas others were personalized based on the patient's medical his-
tory, diagnosis, and current health status. The standardized data in-
cluded age, gender, lifestyle characteristics, diagnosis, anthropometric
measures, a mandatory set of laboratory assessments, and the EQ-5D-
5 L questionnaire. Lifestyle characteristics were recorded in the elec-
tronic patient record by nurses. Physicians' diagnoses were in ac-
cordance with the International Statistical Classification of Diseases and
Related Health Problems (10th revision, ICD-10). Anthropometric
measures were also assessed by a physician and included weight,
height, pulse, and systolic and diastolic blood pressure. Body mass
index (BMI) was derived by dividing the weight in kilograms by the
square of the height in meters. The mandatory set of laboratory as-
sessments included kidney function (plasma creatinine and estimated
glomerular filtration rate (eGFR)), hemoglobin A1c (HbA1c), he-
moglobin, and objective markers of inflammation (C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR)). Comorbidities were
assessed using the age-adjusted Modified Charlson Comorbidity Index
(mCCI) [11]. This index was calculated by the sum of physician and
patient reported comorbid conditions: diabetes mellitus, chronic ob-
structive pulmonary disease (COPD), myocardial infarction, congestive
heart failure, peripheral vascular disease, cerebrovascular disease,
peptic ulcer disease, dementia, kidney disease, leukemia, lymphoma,
solid-tumor cancer, liver disease, hemiplegia and AIDS. Age-adjustment
was done adding one point for every decade age 50 years and over, with
a maximum of four points. The maximum score is 38 points.
Each patient received an invitation to complete the EQ-5D-5 L
questionnaire online after the hospital visit by automated email [12].
Patients completed the questionnaire within a mean of 12 days after the
invitation was sent. Each completed questionnaire was automatically
stored in the electronic patient record. The patient scored each di-
mension from 1 to 5 (1 = no problem, 2 = slight problem, 3 = some
problem, 4 = moderate problem, 5 = extreme problem). The five di-
mensional scores were subsequently used to calculate one overall utility
score, which ranges from 0 (worst) to 1 (best; no problems in any of the
dimensions) [13]. The questionnaire also includes a 20 cm visual ana-
logue scale (VAS) that patients used to self-rate their current overall
health status. Studies have shown that the minimal clinical important
difference (MCID) of the EQ-5D-5 L utility score and VAS are 0.08 and
10 points, respectively [14]. This threshold value of change in score can
be used to interpret the significance of results from a clinical point of
view.
The personalized data that was extracted from the electronic patient
file after the hospital visit had been completed included referral in-
formation, disease duration, and medication use, all of which were
recorded by a physician. We defined disease duration as the number of
months between the visit date and the month and year in which the
patient was diagnosed. The medication data in the electronic patient
files is routinely verified, and corrected if needed, by hospital pharmacy
staff using a national electronic system in which all pharmacies in the
Netherlands participate. We defined past treatment as a treatment re-
ceived during a period of at least 6 weeks but discontinued prior to
enrollment. We defined current treatment as a treatment that the pa-
tient received within 6 weeks after enrollment.
2.3. Data-analysis
We used descriptive statistics to summarize sociodemographic and
clinical characteristics. The EQ-5D-5 L data were presented and ana-
lyzed as utility scores in a continuous manner as well as in categories
(low < 0.70, intermediate 0.70–0.85, and high > 0.85). Pearson's Chi-
square test and ANOVA were used to test for differences between
groups in the case of categorical and continuous variables, respectively.
Potential determinants of HR-QoL were selected a priori, and each of
these were tested in bivariable multinomial logistic regression analysis
with the HR-QoL utility score as a categorical outcome. Those that were
statistically significantly associated with the outcome at p < .05 were
added to a multivariable multinomial logistic regression model with the
same outcome. Statistical analyses were performed using IBM SPSS
version 25 (IBM Corp., Armonk, NY, USA).
3. Results
3.1. Patient characteristics
The analyses included data from all 530 new patients who were
enrolled in the three departments between 7 February 2017 (the start of
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the study) until 29 November 2018. Their mean age was 49 years
(range 18–92) and 67.5% were women (Table 1). Patients were diag-
nosed with a connective tissue disease (32.6%), uveitis (without con-
comitant connective tissue disease) (20.8%), inflammatory arthritis
(17.7%), psoriasis (15.5%), vasculitis (6.2%), primary antiphospholipid
syndrome (APS) (4.2%), or an autoinflammatory disease (2.8%). Con-
nective tissue diseases included mostly SLE (52.9% of those with con-
nective tissue diseases), systemic sclerosis (18.4%), and Sjogren's syn-
drome (16.1%), but also mixed connective tissue diseases (6.9%) and
inflammatory myopathies (4.0%). Inflammatory arthritis included
mostly rheumatoid arthritis (RA) (47.9% of those with inflammatory
arthritis), but also ankylosing spondylitis (16.0%), psoriatic arthritis
(15.9%), and juvenile idiopathic arthritis (12.8%). Of all patients,
10.9% (n = 63) received care in all three departments, 16.0% in the
Rheumatology and Dermatology departments, 14.3% in the Rheuma-
tology and Ophthalmology departments, and 0.5% in the Dermatology
and Ophthalmology departments, over the past five years (Fig. 1).
The majority of participants were current (16.6%) or past smokers
(44.4%). The mean number of pack years reported by current and past
smokers combined was 13 years (95% confidence interval (CI)
11–15 years). Overall mean BMI was 26.2 (95% CI 25.7–26.8). Patients
enrolled by the dermatology department had a significantly higher BMI
(28.0) compared to patients enrolled by the ophthalmology (26.8) and
rheumatology departments (25.6) (p < .01). Mean systolic blood
Table 1
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pressure was 135 mmHg (95% CI 130–140) and mean diastolic blood
pressure was 82 mmHg (95% CI 81–83). Patients with uveitis had a
significantly higher mean systolic blood pressure (147 mmHg) than the
other IMID patients (p = .04).
3.2. Medication use
At the time of the hospital visits, patients were either on mono-
therapy (24.3%), combination therapy (45.1%), or no therapy (30.6%).
Current monotherapies comprised of NSAIDs (16.3%), corticosteroids
(36.4%), cDMARDs (31.8%), or bDMARDs (15.5%) (Table 1). Medica-
tion use differed across the departments. cDMARDs (as part of either
monotherapy or combination therapy) were currently used by 45.5%,
17.0%, and 9.1% of patients in the departments of Rheumatology,
Ophthalmology, and Dermatology, respectively, and bDMARDs by
17.0%, 2.8% and 45.5%, respectively.
3.3. Comorbidity
The mean mCCI was 1.2 (95% confidence interval (CI) 1.1–1.3).
Patients with APS and autoinflammatory disease had the lowest mean
index (0.90, 95% confidence interval (CI) 0.4–1.3 and 0.70, 95% con-
fidence interval (CI) 0.1–1.3, respectively). Patients with vasculitis had
the highest mean mCCI 2.0, 95% confidence interval (CI) 1.4–2.6).
Cancer (N = 36) and diabetes mellitus (N = 33) were most frequently
reported comorbidities. Patients with uveitis had more often a diagnosis
of cancer (N = 16, 14.5%, p = .02) compared with the other diagnoses.
There were no other significant differences between the other comorbid
conditions.
3.4. HR-QoL
All patients combined had a mean EQ-5D-5 L utility score of 0.75
(95% CI 0.72–0.78) (Table 3). When divided in the three categories,
36.5% had a high (> 0.85), 36.8% an intermediate (0.70–0.85), and
26.7% a low utility score (< 0.70). Patients with inflammatory arthritis
had the lowest (0.71, 95% CI 0.66–0.76) and patients with uveitis the
highest mean utility score (0.85, 95% CI 0.80–0.90). The mean current
health status VAS score was 68.8 (95% CI 66.7–70.9), and this score
was lowest in vasculitis patients (59.2, 95% CI 50.0–68.4) and highest
in uveitis patients (77.8, 95% CI 73.3–82.3). The EuroQol subdomains
mobility, selfcare and usual care were also significantly different be-
tween IMIDs (see Table 2). Patients with vasculitis scored significantly
higher, meaning more impairment, on the domain usual activities and
anxiety and depression compared to the other IMIDs. In the mobility
domain, patients with autoinflammatory diseases and inflammatory
arthritis had a significantly higher score. Patients with uveitis had the
lowest scores in all domains.
3.5. HR-QoL determinants
Variables that were associated with a low EQ-5D-5 L utility score
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Modified Charlson Comorbidity Index
(Mean, 95% CI)
1.2 (1.1–1.3) 1.0 (0.8–1.2) 1.7 (0.6–1.3) 2.0 (1.4–2.6) 0.9 (0.4–1.3) 0.7 (0.1–1.3) 1.6 (1.3–1.9) 1.2 (0.9–1.5) < 0.001
AI, autoinflammatory conditions; APS, antiphospholipid syndrome; bDMARDs, biological disease modifiying antirheumatic drugs; BMI, body mass index; BP, blood
pressure; cDMARDs, conventional disease modifiying antirheumatic drugs; CI, confidence interval; CRP,C-reactive protein (normal range 0-10 mg/dL); CTDs,
connective tissue diseases; ESR, estimated sedimentation rate (normal range 0-20 mg/dL); HbA1c, Hemoglobulin A1c (normal range < 42); IV, intravenous; IA,
inflammatory arthritis; NSAIDs, non-steroidal anti-inflammatory drugs.
1 We used ANOVA for means and Chi-squared for categorical variables.
2 Definition of disease duration: the number of months between the hospital visit and the month and year of diagnosis. There were 105 missing values, for all other
valuables, missing values < 10.
3 Medication to target the inflammatory process was included.
4 In the table, all patients that were stated to use steroids, used topical, oral or intravenous corticosteroids.
5 Current medication use was defined as medications initiated within 6 weeks following inclusion.
6 Medication history was defined as medications received for a period of at least 6 weeks but discontinued prior to inclusion. Patients could either use no therapy,
monotherapy or combination therapy.
7 Other medication combinations: immunoglobulins intravenous or autologous stem cell transplantation.
Fig. 1. Overview of patient appointments in the three departments over the last
five years (in 530.
patients).
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rheumatological IMIDs or psoriasis (compared to uveitis), shorter dis-
ease duration, higher ESR, smoking or having smoked in the past, and
currently using bDMARDs. In the multivariable multinomial model, all
these variables with the exceptions of disease duration and ESR re-
mained significant. Subgroup analysis of risk factors in the IMID cate-
gories was not possible because of small numbers in each category. (See
Table 4.)
4. Discussion
Our study assessed and compared HR-QoL in patients with IMIDs in
a unique multidisciplinary cohort. Patients with IMIDs had a lower
mean HR-QoL EQ-5D-5 L utility score (0.75) compared to the general
Dutch population (0.89) [15]. Furthermore, we found differences in
HR-QoL across IMIDs: patients with inflammatory arthritis, vasculitis
and psoriasis had the lowest mean score and patients with uveitis the
highest. A low utility score (< 0.70) was significantly associated with
female sex, rheumatological IMID or psoriasis (compared to uveitis),
current or past smoking, and current use of bDMARDs in a multi-
variable model. Also, in the analysis of the separate domains of the EQ-
5D-5 L, there were significant differences between IMIDs, with regard
to mobility, usual activities, selfcare and anxiety and depression. Var-
iation in HR-QoL between IMIDs was observed in other cohorts from
Rheumatology departments in Western societies as well. A Canadian
cohort investigated HR-QoL in rare CTDs using the SF-36 [16]. Patients
with myositis (N = 25) had lower scores in the physical and mental
domains compared to patients with SLE (N = 118), systemic sclerosis
(N = 108) and RA (N = 64). In another Canadian study comparing
subjects with systemic sclerosis (N = 34), SLE (N = 74) and RA
(N = 42), scores were lowest in SSc and best in SLE [17]. In a Nor-
wegian study, HR-QoL was assessed in patients with RA (N = 3898)
and psoriatic arthritis (N = 1515), using the SF-36 [7]. In both groups,
HR-QoL was decreased compared to the general Norwegian population
and similar between the patient groups. After six months of DMARD
treatment, HR-QoL scores improved in both groups, although the gain
was larger in RA patients.
The differences observed within IMIDs in our study could reflect the
disease-specific symptoms and related impairments. The high HR-QoL
index scores in the uveitis patients in our study, may be because of the
lack of systemic symptoms that impair mobility and produce pain. They
might also be explained by a relatively mild disease activity, illustrated
by a low consumption of anti-inflammatory medication.
We found that current bDMARD users had a lower HR-QoL com-
pared to patients who did not use bDMARDs. This could be due to re-
verse causality: these patients likely had higher disease activity that
triggered treatment by bDMARDs. Longitudinal data are needed to
determine if bDMARD use eventually improves HR-QoL. In longitudinal
studies by others, a good clinical response to bDMARDs was correlated
with better HR-QoL in RA, psoriatic arthritis, and psoriasis patients
[18,19]. Current and past smoking was associated with poorer HR-QoL
scores. This is in line with several earlier reports that also showed a
negative association of smoking and HR-QoL both in the general po-
pulation and in patients with chronic IMIDs [20–24]. In addition, in
many inflammatory conditions, tobacco use has been shown to be as-
sociated with disease activity and organ damage [25,26].
Our study had some limitations. We were not able to recruit all new
Table 3
Bivariable and multivariable analyses of factors associated with HR-QoL, using multinominal logistic regression.1
Variable Bivariable
(ref > 0.85)
RRR (95% CI) p-value Multivariable
(ref > 0.85)
RRR (95% CI) p-value2

































































































































Therapy (ref: no current treatment) (N = 307)
− NSAIDs and/or steroids
− Monotherapy cDMARDs (with/without combination,
bDMARD use excluded)











































BMI, body mass index; bDMARDs, biological disease modifying antirheumatic drugs, cDMARDs, conventional disease modifying antirheumatic drugs; CRP, CTDs,
connective tissue diseases; ESR, estimated sedimentation rate; iv, intravenous; mCCI, modified Charlson Comorbidity Index, NSAIDs, non-steroidal anti-inflammatory
drugs; RRR, relative risk ratio.
1 Variables that had a p-value of < 0.10 in the bivariable logistic multinominal logistic regression analysis were included in the multivariable analysis.
2 P-values < .05 are shown in bold.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J. Spierings, et al. Clinical Immunology 214 (2020) 108392
7
patients with relevant IMIDs during the enrollment period and we did
not take a random sample of them either. Our sample is, therefore, a
convenience sample. This means that the results may not be general-
izable to other patient populations. In addition, the data reported here
are cross-sectional and can therefore not assess changes over time. We
did not collect data on disease-specific disease activity scores. It would
have been of interest to correlate such activity scores to the CRP and
ESR measurements and the HR-QoL utility scores. However, because
our study included patients with several different IMIDs, direct com-
parisons between such scores would have been difficult, and for some
IMIDs, no consensus disease activity scoring system exists. Finally, we
used the EQ-5D-5 L questionnaire, while earlier studies often used the
SF-36 questionnaire. Direct comparisons between our study and these
older studies are therefore not possible. However, we prefer the EQ-5D-
5 L over the SF-36 because it is more concise and easier to complete.
The strength of this study is that we enrolled a large number of
patients with different IMIDs from different departments in our hospital
using standardized assessment of HR-QoL and several other important
variables. To our knowledge, this is the first multidisciplinary IMID
cohort in which HR-QoL was assessed in such a large group of patients.
5. Concluding remarks
In conclusion, we identified differences in HR-QoL across IMIDs in a
large, multidisciplinary cohort in the Netherlands. Several factors were
associated with a decreased HR-QoL. The results from our study in-
dicate that HR-QoL and the contributing factors deserve attention in
care in patients with IMIDs. Long-term follow up is warranted to
monitor HR-QoL over time and assess the impact of interventions on
HR-QoL.
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